The study was undertaken during the period from July to November 2005, for the first time, to determine the efficacy of thermostable PPR vaccine incubated at -20 0 C and room temperature (RT) for 14 days which was developed by Bangladesh Livestock Research Institute (BLRI), Savar, Dhaka, in collaboration with and Livestock Research Institute (LRI), Mohakhali, Dhaka. A total of 80 healthy goats of both sexes, aged between 8 to 36 months were divided into three groups as A, B and C. Group A and B comprised of 30 goats each and received thermostable PPR vaccine kept at -20 0 C and at room temperature (RT) respectively for 14 days, at a dose rate of 1 ml (4 Log 10 TCID 50 / ml) per goat subcutaneously while group C comprising 20 goats served as non-vaccinated control. At 30 days postvaccination, 3 goats from each vaccinated and non-vaccinated group were challenged with 1 ml (5 GID 50 ) of virulent PPR virus per goat subcutaneously in the mid cervical region. Sera samples were collected from all the groups at pre-and post-vaccination (15 and 30 days postvaccination) and were tested for anti-PPR antibody by competitive enzyme linked immunosorbent assay (C-ELISA). In case of group A, average percent inhibition (PI) values of the sera samples at prevaccination and at 15-and 30 days post vaccination were 11.0 ± 5.7, 62.8 ± 9.9 and 81.5 ±5.9 respectively and in case of group B, were 10.0 ± 4.1, 60.7 ± 9.4 and 79.3 ± 7.2 respectively, which were significantly (p < 0.01) higher than those of nonvaccinated control goats (6.3 ± 3.4, 10.2 ± 3.3 and 13.6 ± 3.7 respectively). The titres of vaccinated goats gradually increased until 30 days postvaccination. The challenge test with virulent PPR virus at 30 days post vaccination showed that the thermostable PPR vaccine with both incubation temperatures at -20 0 C and RT for 14 days protected all the goats (100%) of groups A and B respectively while all the non-vaccinated control goats were not protected after challenge showing clinical signs of PPR and / or mortality. From the above findings it may be concluded that the thermostable PPR vaccine can be kept at normal environmental temperature (25 0 -30 0 C) as long as 14 days without loss of its potency and may be used to prevent PPR in goats in field condition.
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INTRODUCTION
Peste des Petits Ruminants (PPR), also known as pseudorinderpest, goat plague, Kata, pneumoenteritis complex, goat catarrhal fever (Chakrabarti, 2003) , is a viral disease of small ruminants (sheep and goats) characterized by an erosive stomatitis, a catarrhal inflammation of the ocular and nasal mucous membranes, profuse diarrhoea, mortality may reach up to 60-70%. In Bangladesh, the PPR virus was identified during a severe outbreak in 1993 (Sil et al., 1995) which was further confirmed by World Reference Laboratory and found that the virus has a close relation with Indian isolates (West Bengal) of PPR virus at a cluster with Asian group (Barrett et al., 1997) . PPR being an exotic disease in Bangladesh, there is a very little knowledge about its epidemic nature, diagnostic techniques and control strategy (Sil et al., 2000 . A control programme using locally produced tissue culture live attenuated rinderpest vaccine (TCV), as well as imported rinderpest vaccine were adapted against PPR in this country, but failed (Sil et al., 1995) . To overcome the problem, a homologous PPR live vaccine was developed, but the main disadvantage of this vaccine, like other Morbillivirus vaccine, is its poor thermal stability (Diallo, 2002) . Although, lyophilization and stabilizing excipients have conferred marginal stability on many vaccines, the development of adequately thermostable vaccine has historically been hindered by the inherent lability and complex nature of the vaccine entities (Rexroad et al., 2002) . To solve this problem, a thermostable PPR vaccine has been developed experimentally by scientists of BLRI and DLS (Chowdhury et al., 2004) . Therefore, the present study was undertaken for the first time in Bangladesh, to determine the efficacy of the thermostable PPR vaccine incubated at room temperature for 14 days. 
MATERIALS AND METHODS

Vaccine and vaccination
A thermostable PPR live homologous vaccine developed by Bangladesh Livestock Research Institute (BLRI), Savar, Dhaka, in collaboration with and Livestock Research Institute (LRI), Mohakhali, Dhaka (Chowdhury et al., 2004 ) was used in this study. A total of 80 healthy goats from 2 villages (Monidia and Chakhalgram) at Savar, Dhaka, of both sexes, aged between 8 to 36 months were divided into three groups as A, B and C. Group A and B comprised of 30 goats each and received thermostable PPR vaccine kept at -20 0 C and at room temperature (RT) respectively for 14 days, at a dose rate of 1 ml (4 Log 10 TCID 50 / ml) per goat subcutaneously while group C comprising 20 goats served as non-vaccinated control. Serum analysis with competitive enzyme linked immunosorbent assay (C-ELISA) was done before vaccination to found PPR antibody negative goats. Whole blood samples were collected by disposable plastic sterile syringes from all the groups at prevaccination and at 15 and 30 days post vaccination. The sera samples were stored at -20 0 C until tested.
C-ELISA
A commercial PPR C-ELISA kit, jointly produced by BDSL, Flow Laboratories and Institute for Animal Health, Pirbright, Surrey, England was used for ELISA test of the sera collected from vaccinated and nonvaccinated goats. The kit was based on a standard competitive enzyme-linked immunosorbent assay (C-ELISA) technique to determine the presence of anti-PPR antibody in serum as described by Anderson et al. (1991) 
Challenge test
For challenge test, a field pathogenic PPR virus isolated from a PPR affected goat of Gazipur district was used and was collected from Animal Health Research Division of Bangladesh Livestock Research Institute (BLRI). At 30 days post vaccination, 3 goats from each vaccinated and control group were brought to BLRI isolation unit and challenged with 1 ml of virulent PPR virus (PPR virus positive processed 20% tissue homogenate, 5 GID 50 / ml, Chowdhury et al., 2004) subcutaneously in the mid cervical region. The goats were observed daily for recording rectal temperatures, clinical signs, mortality and postmortem lesions (from dead goats) up to 30 days postchallenge.
Statistical analysis
Student's 't'-test and one-way 'ANOVA' (Sprinthall, 1987) were carried out to determine the significance of variation of PI values among the different groups and within the individual vaccinated group at pre-and postvaccination (at 15 and 30 days postvaccination).
RESULTS AND DISCUSSION
Average PI values of sera samples from non-vaccinated control goats (group C) at prevaccination and at 15-and 30 days postvaccination were 6.3 ± 3.4, 10.2 ± 3.3 and 13.6 ± 3.7 respectively (Table 1) , which were negative to PPR antibody (P.I. value < 50 indicates negative). This variation in the mean PI values of control group at different periods of sera collection, were statistically insignificant (p < 0.001) and this minor variation might be due to the managemental system as the study was undertaken at field level. In case of group A (vaccinated with thermostable PPR vaccine kept at -20 0 C), average PI values of the sera samples at prevaccination and at 15 and 30 days postvaccination, were 11.0 ± 5.7, 62.8 ± 9.9 and 81.5 ± 5.9 respectively, which were significantly (p < 0.01) higher than those of non-vaccinated control goats. The PI values gradually increased until 30 days postvaccination. This finding is similar with the reports using normal lyophilized PPR
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vaccine ; Razzaque et al., 2005) where the authors concluded that following vaccination, the antibody titres gradually increased from day to day. In case of group B (vaccinated with thermostable PPR vaccine kept at RT), average PI values of the sera samples at prevaccination and at 15 and 30 days postvaccination, were 10.0 ± 4.1, 60.7 ± 9.4 and 79.3 ± 7.2 respectively, which were significantly (p < 0.01) higher than those of non-vaccinated control goats and also gradually increased until 30 days postvaccination. Results of challenge test (Table 2) revealed that the thermostable PPR vaccines of both incubation temperatures (-20 0 C and RT) for 14 days protected (100%) all challenged goats without any clinical signs of PPR and mortality, even at 30 days postchallenge. The challenged non-vaccinated control goats started to show clinical signs like rise of body temperature from 4-6 days postchallenge which is in agreement with the finding of Taylor (1984) . The phases of clinical sings and its duration, found in this study, were similar with the findings of Khan et al. (2005) . Postmortem reports included enlarged lymphnodes, congestion and consolidation of lungs, zebra-stripping in caeco-colic junction, which support the findings of Khan et al. (2005) .
From the above findings, it may be concluded that the thermostable PPR vaccine can be kept at normal environmental temperature (25 0 -30 0 C) as long as 14 days without loss of its potency and this vaccine can be used at field level to prevent PPR in Bangladesh.
